New Strong Sell Stocks for October 22ndZacks Investment Research · 3 days ago
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™GlobeNewsWire · 4 days ago
New Strong Sell Stocks for October 15thZacks Investment Research · Oct 15, 2026
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile TestsGlobeNewsWire · Oct 8, 2026
Cerenome Launches CNSide® CSF Molecular Profile TestsGlobeNewsWire · Oct 6, 2026
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform TranscriptSeeking Alpha · Sep 30, 2026Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.88 | -$1.31 | Miss |
| May 15, 2026 | -$0.85 | -$1.05 | Miss |
| Mar 12, 2026 | -$0.80 | -$0.83 | Miss |
| Oct 30, 2025 | -$0.50 | -$1.00 | Miss |
| Aug 14, 2025 | -$2.25 | $0.50 | Beat |
| May 30, 2025 | -$6.20 | -$29.75 | Miss |